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    Cell-penetrating peptides are powerful tools in the delivery of drugs, proteins, and nucleic acids 
into cells; therefore, a focus has recently been placed on their development.  In this study, we 
synthesized seven types of peptides possessing three L-arginines (L-Arg) and six L-leucines (L-Leu) 
and/or 1-aminocyclopentane-1-carboxylic acids (Ac5c), and investigated their secondary structures 
and cell-penetrating abilities.  The peptide composed of an equal number of L-Arg, L-Leu, and Ac5c 
formed 310/α-helical structures in TFE solution and exhibited the highest cell-penetrating ability of 
all the peptides examined.  Additional cellular uptake studies revealed that the incorporation of Ac5c 
into peptides led to improved tolerability against serum.  The results of the present study will help 




    Many studies have focused on developing delivery systems for drugs, proteins, nucleic acids, 
and nano-sized materials, the internalization of which is difficulty in cultured cells and animal 
tissues.1-4  A peptide-based system using a cell-penetrating peptide represents a promising delivery 
system.  Several types of cell-penetrating systems have recently been developed for amphiphilic 
peptides and arginine (Arg)-rich peptides.5-11  A cationic guanidino group in the side chain of Arg 
was shown to play a crucial role in the cell-penetrating abilities of Arg-rich peptides.  Therefore, a 
concerted effort has been made to develop novel cell-penetrating peptides based on Arg-rich peptides 
including their derivatives, which possess guanidino functional groups.9-14  Furthermore, the 
structures of the amino acids and amino acid sequences in these peptides may be responsible for the 
marked differences reported in their cell permeabilities, and this may be due to the different secondary 
structures of the peptides.15,16  Appropriate positions of guanidino functional groups in the stable 
helical structures contributed to better cell permeability.  Thus, the design of new cell-penetrating 
peptides is important to control these secondary structures. 
    α-Methylated or cyclic α,α-disubstituted α-amino acids (dAAs) have been shown to induce the 
formation of a stable peptide with a helical secondary structure by being incorporated into 
oligopeptides composed of protein α-amino acids.17-20  The number of the dAAs introduced into the 
peptides and the length of the peptide sequence often affect the types of helical structures, either α-
helix or 310-helix.21-24  Therefore, dAAs have been used as helix inducers to direct functional 
peptides such as catalysts and inhibitors.25-30  dAAs are the powerful tools that are used to design 
peptide foldamers 
    In the present study, we designed cell-penetrating helical peptides, which were equipped with 
the properties of Arg-rich peptides and dAA-containing peptides.  The cell-penetrating peptides 
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described herein were nonapeptides possessing three L-Arg and six L-leucines (L-Leu) and/or 1-
aminocyclopentane-1-carboxylic acids (Ac5c)31,32 (Figures 1a and 1b).  L-Leu and Ac5c had similar 
structures with the same number of carbon atoms in the side chain.  Nonapeptides were known to 
represent the borderline region between α-helical and 310-helical structures.  We speculated that the 
incorporation of the five-membered ring amino acid Ac5c into the peptides may stabilize the helical 
secondary structures, and its number in the peptide sequences may also affect the types of helical 
structures.  Figure 1c showed the α-helical and 310-helical structures formed by the nonapeptides 
designed in the present study.  One α-helical turn consisted of 3.6 amino acid residues and one 310-
helical turn consisted of 3.0 amino acid residues.  Therefore, L-Arg appeared at the half side of the 
α-helical structure, while L-Arg was located in the corner of the triangle of 310-helical structure 
(Figure 1c).  The nonapeptides formed different secondary structures based on the number of Ac5c 
incorporated.  An evaluation of cell-penetrating abilities indicated that peptides with three Ac5c and 
three L-Leu exhibited the highest cell-permeability.  These results will be beneficial for the future 




Peptide Synthesis.  All peptides were synthesized using Fmoc solid-phase methods.  Briefly, 
Fmoc-L-Arg(Pbf), Fmoc-L-Leu, Fmoc-Gly, and Fmoc-Ac5c were used as amino acids, and 
HBTU/HOBt or HATU/HOAt were used as coupling reagents.  The coupling of Fmoc-L-Arg(Pbf), 
Fmoc-L-Leu, and Fmoc-Gly was performed using HBTU/HOBt.  On the other hand, hindered Fmoc-
Ac5c and 5(6)-carboxyfluorescein (5(6)-CF) were introduced into the peptides by HATU/HOAt with 
double coupling.  The peptides synthesized were then purified with reversed-phase HPLC (RP-
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HPLC).  The homogeneity of the purified peptides was verified by analytical RP-HPLC and matrix-
assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) 
(Supporting Information).  Analytical RP-HPLC of peptides 3b and 6b revealed a shoulder peak 
next to a major peak, which may have been due to the 5- and 6-isomers of CF (Supporting 
Information). 
 
Secondary Structures of peptides.  The CD spectra of nonapeptides 1a-7a were measured in 2,2,2-
trifluoroethanol (TFE) solution to obtain information on their secondary structures (Figure 2a).  
Negative maxima at 205–209 nm (π→π*) and 222–225 nm (n→π*) were diagnostic of right-handed 
(P) helical structures.33-36  The ratio of R (θn→π*/θπ→π*) has been used as a parameter to distinguish 
α-helical from 310-helical structures (i.e., R ≈ 1: α-helix; R ≤ 0.4: 310-helix).  The CD spectra, except 
for those of peptides 6a and 7a, showed negative maxima at 204–208 and 221–226 nm, which 
indicated the existence of right-handed (P) helices in TFE solution (Figure 2a).37,38  The intensities 
of negative maxima decreased with increase in the number of Ac5c incorporated, which might be due 
to the difference of the achiral Ac5c and chiral L-Leu residues.  Achiral Ac5c could not control helical 
screw-sense of peptides, leading to a decrease of intensities in CD spectra.  The ratio of R 
(θn→π*/θπ→π*) suggested that the dominant secondary structure of peptides 1a (R = 0.52) and 2a (R = 
0.52) was a 310-helix, while that of peptides 3a (R = 0.71) and 4a (R = 0.68) was a mixture of 310- 
and α-helices and that of peptide 5a (R = 0.96) was an α-helix.  The CD spectra of peptides 6a and 
7a did not have characteristic maxima for helical structures.  Further CD spectra measurements of 
peptides 1a and 4a were performed in CH3CN, 90% CH3CN/H2O, 50% CH3CN/H2O, 10% 
CH3CN/H2O, and H2O solution (Figures 2b and 2c).  In CH3CN solution, peptide 1a formed a 310-
helical structure (R = 0.29) and peptide 4a formed 310/α-helices (R = 0.68).  Peptide 1a markedly 
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changed its secondary structure from a 310-helix to a random coil with increase in the ratio of H2O 
(Figure 2b).  On the other hand, peptide 4a appeared to form a (P) helical structure, even in 50% 
CH3CN/H2O solution (Figure 2c).  However, the intensities of negative maxima at 205–209 nm 
(π→π*) and 222–225 nm (n→π*) were too low to form ideal helices, which implied that the helical 
secondary structures and/or helical screw-sense of peptide 4a were not completely controlled. 
 
Cellular Uptake.  The cellular uptake of peptides 1b-7b into HeLa cells was evaluated at different 
concentrations (Figure 3a) and incubation times (Figure 3b).  Figure 3a revealed that the uptake of 
peptides was slightly enhanced by an increase in the number of Ac5c, reached a maximum at peptide 
4b, which possessed three Ac5c, and then decreased to peptide 7b.  The cellular uptake of peptide 
4b was significantly higher than that of the others, especially at low concentrations of 25, 50, and 100 
nM (P < 0.01).  The cellular uptake of peptide 4b was also more efficient than that of the others at 
all incubation times (Figure 3b).  An incubation period of approximately 2 h was optimal for all the 
peptides examined.  The decrease observed in cellular uptake at longer incubation times appeared 
to be influenced strongly by the lower number of Ac5c in peptides.  The cellular uptake of peptides 
1b and 2b with 24- and 36-h incubation periods was markedly lower than that with the 2-h incubation, 
while that of peptides 6b and 7b was not. 
  The cellular uptake of peptides 1b, 4b, and 6b after the pre-incubation of each peptide with medium 
containing serum was evaluated in order to determine why the cellular uptake of peptide 4b was the 
highest (Figure 4a).  Peptides and proteins are easily degraded by proteases in the serum; therefore, 
the tolerability of peptides to proteases could be investigated in this experiment.  The cellular uptake 
of peptide 1b, which had no Ac5c, was markedly lower than that of peptide 4b and 6b following an 
increase in the pre-incubation.  The cellular uptake of peptide 6b remained unchanged even after a 
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2-h pre-incubation (6b vs 1b and 4b, P < 0.01).  These results indicated that the incorporation of 
Ac5c into peptides enhanced their stability in medium containing serum. 
    An additional cellular uptake experiment was performed with post-incubation after the 
replacement of peptide-containing medium with fresh medium in order to gain further insights into 
peptides 1b, 4b, and 6b (Figure 4b).  All peptides showed similar results in that 50% of all the 
peptides examined were eliminated from the HeLa cells after the 4-h post-incubation, which implied 
that all peptides had the same fate after their cellular uptake. 
 
Confocal Laser Scanning Microscopy (CLSM) Observations.  Drug delivery vehicles sometimes 
possess different cellular uptake mechanisms and intracellular destinations depending on the 
structures of vehicles.39-42  The intracellular distribution of peptides 1b, 4b, and 6b (green) was 
investigated using CLSM (Figure 5).  LysoTracker Red (red) and Hoechst33342 (blue) were used to 
label late endosomes/lysosomes and nuclei, respectively.  The intensity of the observed green 
signals was the highest in HeLa cells treated with peptide 4b (Figures 5a-c), which was consistent 
with the cellular uptake results shown in Figure 3.  The intracellular distribution of all three peptides 
was mainly observed as yellow spots and also as green spots.  Furthermore, internalization of each 
peptide into the HeLa cells was confirmed by CLSM observations with treatment of trypan blue 
(Figure S5), which was consistent with the results in Figure 5.  Trypan blue was known not to 
permeate the cell membrane and to quench extracellular fluorescent probes.43,44  The colocalization 
of the peptides with late endosomes/lysosomes was quantified and is shown in Figure 5d.  All 
peptides showed similar colocalization ratios at approximately 40% and were not significantly 
different.  The distribution of peptides was not observed in the nuclei of HeLa cells treated with all 
three peptides.  These results indicated that the peptides described here appeared to be internalized 
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into HeLa cells via the same mechanism regardless of the number of Ac5c or the secondary structures 




    In the present study, two distinctive functions, that of Arg-rich peptides and also that of dAA-
containing peptides, were integrated into the design of cell-penetrating peptides.  The five-
membered ring dAA, Ac5c, was used to modulate the secondary structures of peptides.  CD spectra 
revealed that the dominant structures of nonapeptide 1a-7a in TFE solution differed according to the 
number of Ac5c introduced (Figure 2a).  Peptide 1a, which had no Ac5c, formed a 310-helical 
structure, while peptide 5a, which had four Ac5c, formed an α-helical structure.  Increasing the 
number of Ac5c enhanced the α-helicity of the peptides examined.  Nonapeptides 6a and 7a in TFE 
solution showed no characteristic maxima for helical structures.  Two explanations have been 
proposed.  The first is that there were more achiral amino acids in nonapeptides 6a and 7a than in 
the other peptides, leading to an inability to control the helical screw-sense.  Equal amounts of right-
handed (P) and left-handed (M) helices should show almost no maxima in the CD spectrum.  The 
second is the formation of aggregates.  Aggregation was sometimes detected with high 
concentrations of peptide 7a.  The CD spectrum measurement of nonapeptide 7a may not have been 
conducted correctly.  Additional CD spectra measurements of peptides 1a and 4a in CH3CN/H2O 
solution revealed the stability of their helical secondary structures against H2O.  Peptide 1a could 
not form helical structures, even in 90% CH3CN/H2O solution, while peptide 4a partially maintained 
helical structures, even in 50% CH3CN/H2O solution.  Furthermore, peptide 2a showed similar 
results of peptide 1a and peptide 3a could not form helical structures in 50% CH3CN/H2O solution 
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(Figure S3).  These results demonstrated that the incorporation of Ac5c in peptides stabilized their 
helical structures, even in aqueous solution. 
    Cellular uptake experiments indicated that peptide 4b, which had three Ac5c, exhibited the 
highest cell permeability of all the peptides examined (Figure 3).  It is worth mentioning that the 
cellular uptaken amount of peptide 4b was significantly higher than that of HIV-TAT peptide (Figure 
S4), which was one of the most famous Arg-rich cell-penetrating peptides.45  The dominant structure 
of nonapeptide 4a was 310/α-helices in TFE solution (Figure 2a).  The helicity of peptide 4a was 
partly maintained in 50% H2O solution, while that of peptide 1a-3a was not (Figures 2b, 2c, and S3).  
As shown in Figure 1c, if the peptides described in the present study formed a 310-helical structure, 
L-Arg was located in one corner of the triangle.  Previous study examining amphiphilic α-helical 
cell-penetrating peptides reported that it was important for the function of these peptides to 
concentrate hydrophobic amino acids and cationic amino acids in one direction.15,16,46  The 310-
helical structure is more appropriate for the peptides designed here than the other structures, including 
the α-helical structure, due to the concentration of L-Arg in one region.  This appeared to be one 
reason why peptide 4, which formed 310/α-helices in TFE solution and maintained its helicity even 
in 50% H2O solution, exhibited the highest cell permeability.  The pre-incubation of peptides in 
medium containing serum affected their cell permeability in a manner that depended on the number 
of Ac5c and pre-incubation times.  These results indicated that peptides with Ac5c may have acquired 
tolerability to the proteases in the serum (Figure 4a).  Ac5c was a non-proteinogenic amino acid and 
thus the proteases may have hydrolyzed the peptides containing Ac5c slowly.  The incorporation of 
dAAs into peptides was previously reported to result in protease resistance, more so than in peptides 
composed of natural α-amino acids only,47-50 which is consistent with our results.  Cellular uptake 
experiments with post-incubation after the replacement of peptide-containing medium with fresh 
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medium did not significantly affect the peptides 1b, 4b, and 6b (Figure 4b).  CLSM observations, 
in which the colocalization of the peptides examined with late endosomes/lysosomes was evaluated, 
revealed that all three peptides: 1b, 4b, and 6b, were distributed to similar regions following their 
cellular uptake (Figure 5).  Taken together with these results (Figures 4b and 5), the peptides 
examined in the present study were internalized into the HeLa cells by the same routes and had the 
same fate.  Peptide 4b was internalized into HeLa cells better than the other peptides, and this was 
attributed to synergistic effects between the 310-helical secondary structure and tolerability to 
proteases.  However, the formation of a complete right-handed (P) 310-helical structure was not 
achieved in the present study.  The introduction of achiral Ac5c into the peptides led to change in 
the preferred secondary structures from 310-helix to α-helix and decrease in the right-handed helicity.  
Further mechanistic investigations of 310-helical cell-penetrating peptides are warranted to develop 
more effective cell-penetrating peptides using strictly-controlled 310-helical peptides. 
 
CONCLUSIONS 
    We designed and synthesized seven types of nonapeptides possessing three L-Arg and six L-Leu 
and/or Ac5c for the cell-penetrating peptides.  The number of Ac5c introduced had an effect on the 
secondary structures of the peptides.  Peptide 4, which had three Ac5c, preferred 310/α-helices and 
showed the strongest cell-penetrating ability.  These results are the successful demonstrations of 






General.  All commercial materials were used without further purification.  Fmoc-L-Leu and 
piperidine were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan).  Fmoc-Ac5c 
was obtained from Watanabe Chemical Industries Co., Ltd. (Hiroshima, Japan).  Fmoc-L-Arg(Pbf), 
Fmoc-Gly, and CLEAR-Amide resin were purchased from the Peptide Institute., Inc. (Osaka, Japan).  
HBTU, HOBt, HATU, and HOAt were the products of AAPPTec (Louisville, KY).  
Triisopropylsilane (TIS), 5(6)-CF, acetonitrile, and Dulbecco’s modified Eagle’s medium (DMEM) 
were obtained from Sigma-Aldrich Co. (St. Louis, MO).  N,N-Dimethylformamide (DMF), Cell 
lysis buffer M, and TFE were purchased from Wako Pure Chem. Co., Inc. (Osaka, Japan).  Diethyl 
ether was the product from Kanto Chemical Co., Inc. (Tokyo, Japan).  Trifluoroacetic acid (TFA) 
was obtained from Nacalai Tesque, Co., Inc. (Kyoto, Japan).  Hoechst33342 was purchased from 
Dojindo Laboratories (Kumamoto, Japan).  LysoTracker Red was obtained from Molecular Probes 
(Eugene, OR).  The micro bicinchoninic acid (BCA) protein assay reagent kit was from Thermo 
Fisher Scientific, Inc. (Rockford, IL). 
 
Synthesis and Characterization of Peptides.  The peptides were synthesized on solid support by 
Fmoc solid-phase methods using standard commercially available Rink amide resin and Fmoc-amino 
acids.  The following describes a representative coupling and deprotection cycle at 76-100 µmol 
scales.  First, 200-263 mg of CLEAR-Amide resin (loading: 0.38 mmol/g) was soaked overnight in 
DMF.  After DMF had been removed, 20% piperidine in DMF was added to the resin for 
deprotection.  After removing and washing out piperidine, Fmoc-amino acid (3 equiv) and 
HBTU/HOBt or HATU/HOAt (3 equiv) dissolved in DMF (1.4 mL) were added for the coupling 
reaction (coupling reagents: HBTU/HOBt for Fmoc-L-Leu, Fmoc-L-Arg(Pbf), and Fmoc-Gly; 
HATU/HOAt for Fmoc-Ac5c and 5(6)-CF with double coupling).  The resin was then suspended in 
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cleavage cocktail (TFA: 1.9 mL; H2O: 50 µL; TIS: 50 µL).  The TFA solution was evaporated to a 
small volume and added to cold diethyl ether to precipitate the peptides.  The dried crude peptides 
were dissolved in acetonitrile and/or H2O, and then purified by RP-HPLC using a COSMOSIL 
Packed Column 5C18-AR-II (20 ID x 250 mm) (Nacalai).  Freeze-drying afforded colorless or 
yellow crystals, which were characterized by analytical RP-HPLC (COSMOSIL Packed Column 
5C18-AR-II, 4.6 ID x 250 mm) and MALDI-TOF-MS (Bruker Daltonics Ultraflex, Fremont, CA).  
RP-HPLC was performed utilizing JASCO-PU-2089 Plus (JASCO, Tokyo, Japan) with a JASCO-
2075-Plus as a detector, with being both controlled by JASCO BORWIN software.  Solvent A: 
0.05% TFA in H2O; solvent B: 0.05% TFA in acetonitrile.  The purification procedure required 
gradient conditions (from 95% to 50% solvent A over 20 min) with a flow rate of 10 mL/min and 
detection at 220 nm.  The purity of the final compounds was further confirmed using similar RP-
HPLC conditions (from 95% to 35% solvent A over 20 min, then from 35% to 10% solvent A over 5 
min); however, the flow rate was changed for 1 mL/min. 
 
CD Spectrum Measurement.  CD spectra were recorded with a JASCO J-725N spectropolarimeter 
(JASCO) using a 1.0 mm path length cell.  Data are expressed in terms of [Θ]R, in other words, 
residue molar ellipticity (deg·cm2·dmol-1).  TFE, CH3CN, and H2O were used as solvents. 
 
Cellular Uptake.  HeLa cells were seeded onto 96-well culture plates (10000 cells/well) and 
incubated in 100 µL of DMEM containing 10% fetal bovine serum (FBS).  The medium was then 
replaced with fresh medium containing 10% FBS, and a peptide solution was added to each well at 
an appropriate concentration (Figure 3) and at 100 nM (Figure 4b).  In the case of Figure 4a, the 
medium was replaced with pre-incubated medium (containing 10% FBS), which had been incubated 
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with 100 nM of each peptide at 37˚C for 0.5, 1, or 2 h.  After each time incubation (Figure 3) and a 
2-h incubation (Figure 4a), the medium was removed, and the cells were washed 3 times with ice-
cold PBS supplemented with heparin (20 units/mL) and then treated with Cell lysis buffer M.  In the 
case of Figure 4a, after a 2-h incubation, the peptide-containing medium was replaced with fresh 
medium.  After each post-incubation time, the medium was removed, and the cells were washed 3 
times with ice-cold PBS supplemented with heparin (20 units/mL) and then treated with Cell lysis 
buffer M.  The fluorescence intensity of each lysate was measured using a spectrofluorometer (ND-
3300, NanoDrop, Wilmington, DE).  The amount of protein in each well was concomitantly 
determined using the BCA protein assay reagent kit.  The results are presented as the mean and 
standard deviation obtained from 6 samples (Figures 3a and 4) or 3 samples (Figure 3b). 
 
CLSM observations.  HeLa cells were seeded onto 8-well chambered cover glasses (Iwaki, Tokyo, 
Japan) (20000 cells/well) and incubated overnight in 200 µL of DMEM containing 10% FBS.  The 
medium was then replaced with fresh medium containing 10% FBS, and a peptide solution was 
applied to each well at a concentration of 1 µM.  After a 2-h incubation, the medium was removed, 
and the cells were washed 3 times with ice-cold PBS supplemented with heparin (20 units/mL).  The 
intracellular distribution was observed by CLSM after staining late endosomes/lysosomes with 
LysoTracker Red and nuclei with Hoechst33342.  CLSM observations were performed using LSM 
710 (Carl Zeiss, Oberlochen, Germany) with a Plan-Apochromat 63x/1.4 objective (Carl Zeiss) at an 
excitation wavelength 405 nm (UV laser) for Hoechst33342, 488 nm (Ar laser) for peptides, and 543 
nm (He-Ne laser) for LysoTracker Red.  The rate of the colocalization of peptides with LysoTracker 
Red was quantified.51  The colocalization ratio was quantified as follows: 
    Colocalization ratio (%) = peptide pixelscolocalization / peptide pixelstotal x 100 
 14
where peptide pixelscolocalization represents the number of peptide pixels colocalizing with LysoTracker 
Red in the cell, and peptide pixelstotal represents the number of all the pixels in the cell.  The results 
are represented as the mean and standard deviation obtained from 15 cells. 
 
Statistical Analysis.  Significance was assessed by a 2-tailed Student’s t-test.  P values of less than 





MALDI-TOF-MS data and copies of analytical RP-HPLC of peptides 1a-7a and 1b-7b.  This 
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Ac5c, 1-aminocyclopentane-1-carboxylic acid; BCA, bicinchoninic acid; CD, circular dichroism; CF, 
carboxyfluorescein; CLSM, confocal laser scanning microscope; dAA, α,α-disubstituted α-amino 
acid; DMEM, Dulbecco’s modified Eagle’s medium; DMF, N,N-dimethylformamide; FBS, fetal 
bovine serum; Fmoc, 9-fluorenylmethoxycarbonyl; HATU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate; HBTU, O-benzotriazol-1-yl-N,N,N’,N’-
tetramethyluronium hexafluoro-phosphate; HOAt, 1-hydroxy-7-azabenzotriazole; HOBt, 1-
hydroxybenzotriazole; MALDI-TOF-MS, matrix-assisted laser desorption-ionization time-of-flight 
mass spectrometry; Pbf, 2,2,4,6,7-pentamethyldihyrdobenzofuran-5-sulfonyl; RP, reversed-phase; 
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Figure 1.  The amino acids, peptides, and helical structures described in the present study.  (a) 
Structures of the amino acids, L-arginine (L-Arg), L-leucine (L-Leu), and 1-aminocyclopentane-1-
carboxylic acid (Ac5c).  (b) Sequences of the peptides composed of L-Arg, L-Leu, and Ac5c with or 
without a fluorescent label.  (c) Schematic illustration of the α-helical and 310-helical structures as 




Figure 2.  CD spectra of nonapeptides 1a-7a in TFE solution (a).  CD spectra of nonapeptides 1a 
(b) and 4a (c) in 100% CH3CN, 90% CH3CN/H2O, 50% CH3CN/H2O, 10% CH3CN/H2O, and H2O 




    
Figure 3.  Cellular uptake of peptides 1b-7b.  (a) The peptide concentration-dependency with the 
2-h incubation period.  Error bars represent the standard deviation, n = 6.  (b) The incubation time-






Figure 4.  Cellular uptake of peptides 1b, 4b, and 6b under the experimental conditions of (a) each 
pre-incubation time of peptides in medium containing serum, followed by a 2-h incubation of peptides 
with cells or (b) a 2-h incubation of peptides with cells, followed by a post-incubation of each time 




Figure 5.  Intracelluar distribution of peptides 1b (a), 4b (b), and 6b (c) (green).  Acidic late 
endosomes/lysosomes and nuclei were stained with LysoTracker Red (red) and Hoechst33342 (blue), 
respectively.  The scale bars represent 20 μm.  (d) Quantification of the colocalization of peptides 
with LysoTracker Red.  Error bars represent the standard deviation, n = 15. 
 
 
